Drugs / Flornaptitril
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06254469 | Jul 2025 → Jun 2028 expected | Alzheimer disease, traumatic encephalopathy | CereMark Pharma, LLC | Recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-07-10 | CereMark Pharma, LLC | CereMark Pharma Begins Phase III Trial of F-18 Flornaptitril, a Novel Diagnostic Radiopharmaceutical Focused on Neurodegeneration ceremarkpharma.com ↗ |
| 2023-12-08 | CereMark Pharma, LLC | CereMark Pharma and Invicro to Collaborate on the Development of F-18 Flornaptitril ceremarkpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flornaptitril | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06254469 ↗ |
| Known as | [F-18]Flornaptitril | “Drug: [F-18]Flornaptitril” NCT06254469 ↗ |